These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 32585700)

  • 1. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.
    Kärppä M; Yardley J; Pinner K; Filippov G; Zammit G; Moline M; Perdomo C; Inoue Y; Ishikawa K; Kubota N
    Sleep; 2020 Sep; 43(9):. PubMed ID: 32585700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial.
    Yardley J; Kärppä M; Inoue Y; Pinner K; Perdomo C; Ishikawa K; Filippov G; Kubota N; Moline M
    Sleep Med; 2021 Apr; 80():333-342. PubMed ID: 33636648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder.
    Arnold V; Ancoli-Israel S; Dang-Vu TT; Mishima K; Pinner K; Malhotra M; Moline M
    Neurol Ther; 2024 Aug; 13(4):1081-1098. PubMed ID: 38748321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials.
    Gotfried MH; Auerbach SH; Dang-Vu TT; Mishima K; Kumar D; Moline M; Malhotra M
    Drugs Aging; 2024 Sep; 41(9):741-752. PubMed ID: 39120786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lemborexant in midlife women with insomnia disorder.
    Terauchi M; Cheng JY; Yardley J; Pinner K; Moline M; Malhotra M; Inabe K; Nishida M; Pappadopulos E
    Menopause; 2023 Aug; 30(8):839-848. PubMed ID: 37339396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder.
    Dash A; Pinner K; Inoue Y; Hayashida K; Lim SC; Yun CH; Lan TH; Huang CL; Yardley J; Kubota N; Moline M
    Sleep Med X; 2022 Dec; 4():100044. PubMed ID: 35402894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lemborexant in subjects previously treated with placebo for 6 months in a randomized phase 3 study.
    Yardley J; Inoue Y; Pinner K; Perdomo C; Kubota N; Perlis ML; Moline M
    Sleep Med; 2023 Oct; 110():111-119. PubMed ID: 37574610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder.
    Roth T; Rosenberg R; Morin CM; Yardley J; Pinner K; Perdomo C; Atkins N; Pappadopulos E; Malhotra M; Moline M
    Sleep Med; 2022 Feb; 90():249-257. PubMed ID: 35220140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
    Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
    JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
    Chepke C; Jain R; Rosenberg R; Moline M; Yardley J; Pinner K; Kumar D; Perdomo C; Filippov G; Atkins N; Malhotra M
    Postgrad Med; 2022 Apr; 134(3):316-325. PubMed ID: 35254948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lemborexant in adults with insomnia: comparing Japanese and non-Japanese subgroups from the global, phase 3, randomized, double-blind, placebo-controlled SUNRISE 2 study.
    Inoue Y; Watanabe T; Takashima S; Takase T; Ishikawa K; Kubota N; Yardley J; Moline M
    J Clin Sleep Med; 2021 May; 17(5):1067-1074. PubMed ID: 33576735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
    Murphy P; Moline M; Mayleben D; Rosenberg R; Zammit G; Pinner K; Dhadda S; Hong Q; Giorgi L; Satlin A
    J Clin Sleep Med; 2017 Nov; 13(11):1289-1299. PubMed ID: 29065953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial.
    Takaesu Y; Suzuki M; Moline M; Pinner K; Inabe K; Nishi Y; Kuriyama K
    Clin Transl Sci; 2023 Apr; 16(4):581-592. PubMed ID: 36564964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial.
    Moline M; Thein S; Bsharat M; Rabbee N; Kemethofer-Waliczky M; Filippov G; Kubota N; Dhadda S
    J Prev Alzheimers Dis; 2021; 8(1):7-18. PubMed ID: 33336219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study.
    Mayleben D; Rosenberg R; Pinner K; Hussein Z; Moline M
    Sleep Adv; 2021; 2(1):zpab011. PubMed ID: 37193566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled, crossover study of respiratory safety of lemborexant in moderate to severe obstructive sleep apnea.
    Cheng JY; Lorch D; Lowe AD; Uchimura N; Hall N; Shah D; Moline M
    J Clin Sleep Med; 2024 Jan; 20(1):57-65. PubMed ID: 37677076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
    Cheng JY; Moline M; Zammit GK; Filippov G; Bsharat M; Hall N
    Clin Drug Investig; 2021 May; 41(5):449-457. PubMed ID: 33723806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
    Black J; Pillar G; Hedner J; Polo O; Berkani O; Mangialaio S; Hmissi A; Zammit G; Hajak G
    Sleep Med; 2017 Aug; 36():86-94. PubMed ID: 28735928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of Dimdazenil in adults with insomnia disorder: results from a multicenter, randomized, double-blind, placebo-controlled phase III trials.
    Huang Z; Zhan S; Chen C; Zhang R; Zhou Y; He J; Lin Z; Bao C; Zhu S; Zhao J; Zhang S; Jiang Y; Wang Y
    Sleep; 2024 Feb; 47(2):. PubMed ID: 37875349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials.
    Moline M; Zammit G; Yardley J; Pinner K; Kumar D; Perdomo C; Cheng JY
    Postgrad Med; 2021 Jan; 133(1):71-81. PubMed ID: 33119423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.